CD8A and neoplasm: To ascertain whether TH1579 can enhance the infiltration of CD8+ T cells within the tumour microenvironment, B16F10 allografted mice were subjected to a treatment regimen comprising either a vehicle, TH1579 at a dosage of 90 mg/kg (b.i.d., 3 times a week), atezolizumab at a dosage of 5 mg/kg (q.i.d., twice a week), or a combination of both (Fig. 3B).